SARS-CoV-2 ORF8 Antibody [CoraFluor™ 1]

Novus Biologicals | Catalog # NBP3-11934CL1

Novus Biologicals
100% Guarantee

Key Product Details

Species Reactivity

SARS-CoV-2

Applications

Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot, ELISA

Label

CoraFluor 1

Antibody Source

Polyclonal Rabbit IgG
View all SARS-CoV-2 ORF8 Primary Antibodies »

Product Specifications

Immunogen

Antibody was raised against a peptide corresponding to 14 amino acids near carboxyl terminus of SARS-CoV-2 ORF8 protein. The immunogen is located within the last 50 amino acids of the SARS-CoV-2 ORF8 protein.

Specificity

Antibody is predicted to not cross-react with other coronavirus family members.

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Description

This conjugate is made on demand and is not held in inventory. Each order represents a unique lot. All conjugates are generated using validated conjugation protocols and meet strict degree of labeling (F/P) specifications; additional information is available upon request. The antibody concentration is provided on the individual product label.

For specialized conjugation needs, like large quantities, specific concentrations, and defined F/P ratios, bulk and custom antibody conjugation services are available.

Scientific Data Images for SARS-CoV-2 ORF8 Antibody [CoraFluor™ 1]

SARS-CoV-2 ORF8 Antibody [CoraFluor™ 1]

Product Feature: CoraFluor Probes for TR-FRET

CoraFluor™ 1, amine reactive (Catalog:7920) and CoraFluor™ 2, amine reactive (Catalog # 7950) are terbium-based probes that have been developed for use as TR-FRET donors. They emit wavelengths compatible with commonly used fluorescent acceptor dyes such as BODIPY® (or BDY) and Janelia Fluor® dyes, FITC (Catalog # 5440), TMR and Cyanine 5 (Catalog # 5436). CoraFluor™ fluorescence is brighter and more stable in biological media than existing TR-FRET donors, leading to enhanced sensitivity and improved data generation. CoraFluor™ 1 exhibits excitation upon exposure to a 337 nm UV laser.

Applications for SARS-CoV-2 ORF8 Antibody [CoraFluor™ 1]

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry-Paraffin

Optimal dilutions of this antibody should be experimentally determined.

Western Blot

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Recommended applications are based on validated applications from the unconjugated base product NBP3-11934. This conjugated antibody is not kept in inventory and is made to order using validated conjugation protocols.

Formulation, Preparation, and Storage

Purification

Peptide affinity purified

Formulation

PBS

Preservative

No Preservative

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark. Do not freeze.

Background: SARS-CoV-2 ORF8

SARS-CoV-2 Open Reading Frame 8 (ORF8) is one of the nine downstream accessory protein open reading frames of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19 (1). SARS-CoV-2 ORF8 is 121 amino acids (aa) in length with a theoretical molecular weight of 13.8 kDa (2, 3). One particular difference between SARS-CoV-2 and SARS-CoV is that SARS-CoV-2 has one ORF8 protein, while SARS-CoV has two ORF8 proteins (ORF8a and ORF8b) (3). The aa sequence alignment of SARS-CoV-2's ORF8 has 31.7% sequence identity and 70.7% sequence similarity with SARS-CoV ORF8a (3). Furthermore, SARS-CoV-2 ORF8 has a 40.5% sequence identity and 66.7% sequence similarity is with SARS-CoV ORF8b (3). Despite this low sequence identity and similarity, the ORF8 structure and function appears to be well conserved (4). Both ORF8 proteins appear to be localized to the ER and have an N-terminal hydrophobic region, a conserved glycosylation site, and cysteine residues capable of forming disulfide bonds (4).

Studies have revealed that SARS-CoV-2 ORF8 has a role in host immune suppression during viral infection as it is an inhibitor of the type I interferon pathway (4, 5). Specifically, ORF8 has been shown to have antagonistic properties on interferon-beta (IFN-beta), the NF-kappabeta-responsive promoter, and the interferon-stimulated response element (ISRE) (4,5). Additionally, ORF8 colocalizes with the ER and lysosomal proteins Calnexin and LAMP1, playing a role in major histocompatibility complex class I (MHC-I) downregulation and degradation (4, 6). These results suggest that inhibiting ORF8 may be a potential approach for improving immune surveillance and more quickly eliminating SARS-CoV-2 infection (4-6).

References

1. Michel, C. J., Mayenr, C., Poch, O., & Thompson, J. D. (2020). Characterization of accessory genes in coronavirus genomes. Virology journal. https://doi.org/10.1186/s12985-020-01402-1

2. UniProt (P0DTC8)

3. Yoshimoto F. K. (2020). The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. The protein journal. https://doi.org/10.1007/s10930-020-09901-4

4. Mohammad, S., Bouchama, A., Mohammad Alharbi, B., Rashid, M., Saleem Khatlani, T., Gaber, N. S., & Malik, S. S. (2020). SARS-CoV-2 ORF8 and SARS-CoV ORF8ab: Genomic Divergence and Functional Convergence. Pathogens (Basel, Switzerland). https://doi.org/10.3390/pathogens9090677

5. Li, J. Y., Liao, C. H., Wang, Q., Tan, Y. J., Luo, R., Qiu, Y., & Ge, X. Y. (2020). The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus research. https://doi.org/10.1016/j.virusres.2020.198074

6. Zhang Y., Zhang J., Chen Y., Luo B., Yuan Y., Huang F., Yang T., Yu F., Liu J., Liu B., et al. (2020). The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Potently Downregulating MHC-I. bioRxiv. https://doi.org/10.1101/2020.05.24.111823.

Alternate Names

2019-nCoV ORF8, 2019-nCoV ORF8 Protein, COVID-19 Non-structural protein 8, COVID-19 ns8, COVID-19 ORF8, Human coronavirus ORF8 Protein, Non-structural protein 8, ns8, ORF8 protein, SARS-CoV-2, SARS-CoV-2 Non-structural protein 8, SARS-CoV-2 ns8, SARSCoV2 ORF8 Protein, SARS-CoV-2 ORF8 Protein, Severe Acute Respiratory Syndrome Coronavirus 2 ORF8 Protein

Gene Symbol

ORF8

Additional SARS-CoV-2 ORF8 Products

Product Documents for SARS-CoV-2 ORF8 Antibody [CoraFluor™ 1]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Download SDS

Product Specific Notices for SARS-CoV-2 ORF8 Antibody [CoraFluor™ 1]

Sold for research purposes only under agreement from Massachusetts General Hospital, US Patent No. 12,134,721. A license is required for development of new commercial assay platforms (e.g., microarrays, microfluidics), diagnostic use or other unlicensed uses. Please contact Technical Support for further details: techsupport@bio-techne.com.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Customer Reviews for SARS-CoV-2 ORF8 Antibody [CoraFluor™ 1]

There are currently no reviews for this product. Be the first to review SARS-CoV-2 ORF8 Antibody [CoraFluor™ 1] and earn rewards!

Have you used SARS-CoV-2 ORF8 Antibody [CoraFluor™ 1]?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 for a review with an image

$10/€7/£6/$10CAN/¥1110 for a review without an image

Submit a review
Amazon Gift Card

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies